Anvisa approves medicine to prevent stroke
The unpublished product in the country is an anticoagulant, with the trade name Lixiana (edoxabana). The drug is produced by the Japanese company Daiichi Sankyio Brasil Farmacêutica Ltda.
According to Anvisa, the drug has two specific therapeutic indications:
Reduced risk of stroke or systemic embolism in patients (VTE) in adults, including deep venous thrombosis (DVT) and pulmonary embolism (PE), in addition to recurrent VTE prevention (DVT or PE).
- The drug, edoxaban, is part of the class of new anticoagulants that began to be researched around the year 2000. The drug binds to a compound that coagulates blood (factor Xa), and prevents its action, thus being named therapies of
- Unlike the older drugs, current therapies do not interact with food, increasing the effectiveness of the product and improving the patient's quality of life.
Brazil recorded 588 deaths from the H1N1 virus. According to the document, 188 deaths from H1N1 flu were recorded. In total, there were some 3501 cases of influenza, of which 1604 cases are located in the country. Southeast Region and 1,394 are from the State of São Paulo. Prevention The best way to avoid contamination by the H1N1 virus is prevention.
Stem cells are cells that have the ability to self-renew, that is, to give rise to other stem cells equal to it, and which also have the potential to become other cells To better understand the concept, we must take into account that the human body is made up of a trillion cells and some of them have specific functions.